Maze Therapeutics (NASDAQ:MAZE) Now Covered by JPMorgan Chase & Co.
JPMorgan Chase & Co. started coverage on shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) in a report published on Tuesday morning,Benzinga reports. The brokerage issued an overweight rating and a $30.00 price objective on the stock. Separately, Leerink Partners began coverage on Maze Therapeutics in a research report on Tuesday. They set an “outperform” […]
JPMorgan Chase & Co. started coverage on shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) in a report published on Tuesday morning,Benzinga reports. The brokerage issued an overweight rating and a $30.00 price objective on the stock. Separately, Leerink Partners began coverage on Maze Therapeutics in a research report on Tuesday. They set an “outperform” […]
